United States Patent 5,789,449 (Claims 1-8): Scope, Claim Boundaries, and US Patent Landscape for Serotonin Reuptake Blocker Treatment of Psychiatric Symptoms
What does US 5,789,449 claim, in enforceable terms?
US 5,789,449 is directed to methods of treating psychiatric symptoms by administering a “nontoxic dose” of a serotonin re-uptake blocker. The psychiatric symptom set is narrow and explicitly enumerated, and the pharmacologic set is largely confined to listed SSRIs and related agents.
Core claim elements (common to the independent and dependent framework)
| Claim feature |
What the claim requires |
Practical enforcement consequence in the US |
| Treatment type |
“A method for treating psychiatric symptoms” |
Covers medical method use of a drug (not composition claims) |
| Dosage qualifier |
“administering a nontoxic dose” |
Invokes a dose-limiting limitation; the patentee’s interpretation typically anchors to safe, clinically used dosing |
| Drug class |
“serotonin re-uptake blocker” |
Requires pharmacologic classification as a serotonin reuptake inhibitor (SSRI-like mechanism) |
| Symptom selection |
Symptoms are “selected from” an enumerated group |
If accused use does not target anger, rejection sensitivity, and/or lack of mental or physical energy, the method claim likely does not read |
| PMDs variant |
Separate method for “psychiatric symptoms associated with premenstrual disorders” |
Expands use context to premenstrual-disorder-associated symptomatology |
Enumerated psychiatric symptoms (claim-limiting language)
The claims restrict the target symptoms to:
- Anger
- Rejection sensitivity
- Lack of mental or physical energy
Because the language is “selected from the group consisting of,” each method claim is limited to treatment of one or more of these specific symptom categories. Broader constructs such as “depression,” “anxiety,” “mood disorders,” or “fatigue” outside the claimed symptom framing are not automatically covered.
Drug list scope across dependent claims
The claims name the following serotonin re-uptake blockers (and their pharmaceutically acceptable salts) in the dependent claim sets:
- fluoxetine
- zimelidine
- fluvoxamine
- sertraline
- indalpine
- citalopram
- femoxetine
- paroxetine
- alaproclate
- pharmaceutically acceptable salts
Additional narrower dependent claim coverage:
- Claim 3/7 narrows to fluoxetine or sertraline
- Claim 4/8 narrows further by specifying a daily adult dose of fluoxetine: about 2 mg to about 80 mg
The “about” qualifier provides flexibility but still constrains the asserted dosing window.
What is the scope of each claim (1 through 8), and where are the boundary lines?
H2: Claim 1 scope and the tightest limits
Claim 1 defines the first and broadest operative method set:
- Psychiatric symptoms are limited to: anger, rejection sensitivity, lack of mental or physical energy
- Drug must be a serotonin re-uptake blocker
- Dose must be “nontoxic”
Boundary lines for Claim 1
- Symptom boundary: Uses that target symptoms not in the enumerated set fall outside the literal reading. This matters for clinical coding and labeling language because practitioners often treat broader symptom complexes.
- Mechanism boundary: The method requires a serotonin re-uptake blocker. Drugs with different mechanisms (e.g., SNRIs with distinct additional mechanisms, TCAs with different primary targets, MAOIs) can still be arguable depending on whether they qualify as serotonin reuptake blockers, but the claim framing is anchored to serotonin reuptake blockade.
- Dose boundary: “Nontoxic dose” is a litigation handle. A non-toxic dose reading typically tracks clinically used dosing and safety thresholds; extremely high dosing or intentionally toxic/abusive dosing practices should fall outside the claim.
H2: Claim 2 narrows drug identity to a closed list
Claim 2 limits Claim 1’s serotonin reuptake blocker to one of the enumerated agents:
- fluoxetine, zimelidine, fluvoxamine, sertraline, indalpine, citalopram, femoxetine, paroxetine, alaproclate
- plus pharmaceutically acceptable salts
Boundary lines
- “Selected from the group consisting of” is closed. A serotonin reuptake blocker not on this list is outside Claim 2.
- If an accused product is an SSRI not listed, enforcement against Claim 2 would likely fail, unless the patentee can argue literal capture through inclusion of a listed pharmaceutically equivalent agent or that the accused drug is within the named agent.
H2: Claim 3 narrows further to fluoxetine or sertraline
Claim 3 limits Claim 2 to:
This is a second drug-identity narrowing after Claim 2’s list.
H2: Claim 4 adds a dosing window for fluoxetine
Claim 4 adds a fluoxetine daily adult dosing limitation:
- about 2 mg to about 80 mg per day
Boundary lines
- If an accused method uses fluoxetine outside this window (by a material margin), it likely avoids literal infringement for this dependent claim.
- “About” can still capture near-adjacent regimens, but it is not an unlimited range.
H2: Claims 5 to 8 add the premenstrual disorder symptom context
Claim 5 introduces a different clinical association:
- Method for treating psychiatric symptoms associated with premenstrual disorders
- Psychiatric symptoms are still restricted to: anger, rejection sensitivity, lack of mental or physical energy
- Drug remains a serotonin reuptake blocker at a “nontoxic dose”
Boundary lines
- The claim requires the psychiatric symptoms to be “associated with premenstrual disorders.” If an accused method treats the enumerated symptoms without tying them to premenstrual disorders (clinically or by patient selection criteria), it may not read on Claim 5.
- The “associated with” phrasing is not as strict as “caused by,” but it still imposes a clinical context limitation.
Claim 6 repeats Claim 2’s closed drug list restriction for the PMD-associated symptom set.
Claim 7 repeats Claim 3’s narrowing to fluoxetine or sertraline.
Claim 8 repeats Claim 4’s fluoxetine daily adult dosing window.
How does the claim structure affect infringement risk for generic prescribing?
The patent is a method-of-treatment patent. In practice in the US, enforcement often tracks:
- Which symptom the clinician is targeting (the enumerated symptom set)
- Which patient population is used (especially for PMD-associated symptom methods)
- Which drug is used (closed list in the dependent claims)
- Whether the dosing aligns (fluoxetine dose window)
For generic SSRIs that are already widely used (fluoxetine, sertraline, paroxetine, citalopram, fluvoxamine), the principal infringement risk is not drug identity; it is method fit (symptom targeting and PMD association) and dose for the dependent claims.
Because Claim 1 is broader on drug identity (class-based) but still limited by symptom categories and “serotonin re-uptake blocker” mechanism, it can potentially capture additional serotonin reuptake inhibitors, but the dependent claims anchor the analysis to named SSRIs.
What is the US patent landscape likely connected to this claim set?
H2: Landscape map by claim type: method-of-use vs. composition vs. drug mechanism
The claims here are method-of-use claims over specific psychiatric symptom categories. The enforceable scope is therefore surrounded by:
- Earlier SSRI patents/compositions and process patents (expired or near-expired by the time of this patent’s enforceability, depending on filing dates)
- Later method-of-use patents for psychiatric or PMD-related indications using SSRIs
- Regulatory labeling and clinical practice that may overlap with the symptom categories (especially anger/irritability, fatigue/low energy, and PMD-related mood/behavior changes)
Given that the claims list multiple SSRIs and salts, the landscape risk is less about whether SSRIs exist and more about whether later patents carved out or expanded symptom definitions, dosing regimens, or patient-selection criteria.
H2: Likely overlap clusters from the claim’s symptom taxonomy
The enumerated symptoms are unusual compared with standard psychiatric indication taxonomies. That creates two landscape effects:
- Higher risk of novelty arguments at prosecution: “rejection sensitivity” and the explicit triad (anger, rejection sensitivity, lack of mental or physical energy) may have been used to establish novelty over conventional depression/anxiety indications.
- Higher design-around options for competitors: competitors can potentially avoid literal infringement by focusing on different symptom targets or by structuring trials and labeling around non-enumerated symptom endpoints.
H2: Likely overlap clusters from PMD association
“Premenstrual disorders” is another axis where patent landscapes frequently expand through method-of-use claims, intermittent dosing regimens, and symptom-specific endpoints.
This patent’s PMD claim ties the enumerated psychiatric symptoms to PMD. Landscape overlap is typically with:
- SSRI use for PMDD/PMD affective symptoms
- Dosing regimens for luteal phase or cyclic treatment
- Symptom scales and endpoints for irritability/anger, energy/fatigue, and interpersonal sensitivity
H2: Drug identity overlap created by fluoxetine and sertraline
Claims 3, 7, and 4, 8 focus on fluoxetine and sertraline, with a fluoxetine dose window for adult daily dosing.
The US landscape around fluoxetine/sertraline is dense due to broad approved indications (depression, anxiety disorders, OCD, PTSD, etc.). For infringement analysis against 5,789,449, however, the key is not whether fluoxetine is known as an SSRI, but whether an accused method targets the claimed symptom set (and, for dependent claims, the claimed dosing window).
What are the actionable infringement choke points in this patent?
H2: Symptom targeting and indication design are the primary choke points
Because the claims are limited to “psychiatric symptoms” that are “selected from” a closed list, the infringement analysis turns on what the clinician is treating. The practical choke points:
- If a protocol treats “irritability” or “mood” without framing it as “anger” (as claimed), there is room for non-literal or non-reading arguments.
- If “fatigue” is treated but not “lack of mental or physical energy” (as claimed), the literal fit may differ depending on definitions used in trial protocols and clinical documentation.
- “Rejection sensitivity” is a specific construct; protocols targeting general interpersonal distress without using or aligning to “rejection sensitivity” can be used to argue non-fit.
H2: PMD linkage is the second choke point
For Claims 5-8, the method must treat psychiatric symptoms “associated with premenstrual disorders.” If a competitor’s method targets the same symptoms but in a different population or without PMD association criteria, the PMD method claims do not read cleanly.
H2: Fluoxetine dosing window limits dependent claims 4 and 8
The adult daily dose window of fluoxetine (about 2 mg to about 80 mg) constrains:
- high-dose regimens above the window
- ultra-low-dose strategies below the window
The “about” qualifier still leaves factual room, but it is a clear limitation.
What does this mean for freedom-to-operate (FTO) strategy?
H2: How to assess risk quickly in the US
For products or clinical programs involving fluoxetine/sertraline or other SSRIs, the dominant question is not whether the drug is a serotonin reuptake blocker; it is whether the program:
- targets the enumerated symptoms (anger, rejection sensitivity, lack of mental or physical energy)
- uses patient selection framed around premenstrual disorders for Claims 5-8
- uses a dosing regimen that fits Claims 4 and 8 for fluoxetine
FTO screening typically proceeds by mapping protocol endpoints and inclusion criteria to the claim’s symptom list and, for fluoxetine programs, to the dose window.
H2: Design-around levers visible from the claim text
The claim text indicates several straightforward levers:
- Replace the targeted symptom with a non-enumerated symptom concept in trial endpoints and patient selection
- Avoid the PMD association in the method context (for PMD-based claims)
- For fluoxetine, select a daily adult dose intentionally outside the about 2 mg to about 80 mg range used in the method for infringement risk management
- In dependent-claim contexts, use a serotonin reuptake blocker not included in the enumerated list to avoid Claims 2 and 6 literal reading (while recognizing Claim 1 still depends on the serotonin reuptake blocker class)
Key Takeaways
- US 5,789,449 is a method-of-treatment patent over psychiatric symptoms treated with a “nontoxic dose” of a serotonin reuptake blocker, with a closed symptom list: anger, rejection sensitivity, and lack of mental or physical energy.
- Drug identity becomes narrower in dependent claims via a closed list of named SSRIs (fluoxetine, zimelidine, fluvoxamine, sertraline, indalpine, citalopram, femoxetine, paroxetine, alaproclate) and then further narrows to fluoxetine or sertraline.
- Fluoxetine dosing is limited in dependent claims to about 2 mg to about 80 mg daily.
- Claims 5-8 add a PMD linkage requirement: the psychiatric symptoms must be “associated with premenstrual disorders,” creating an additional population-context limitation.
- The most actionable infringement choke points are symptom targeting, PMD association, and fluoxetine dosing for the dependent claims.
FAQs
-
Is US 5,789,449 limited to SSRIs only?
Claim 1 requires a “serotonin re-uptake blocker.” Dependent claims restrict to a closed list that includes multiple named SSRIs and related serotonin reuptake blockers.
-
Does the patent cover depression or anxiety broadly?
The claims are limited to the enumerated psychiatric symptoms: anger, rejection sensitivity, and lack of mental or physical energy. Generic depression/anxiety language does not automatically satisfy the claim’s symptom set.
-
Can a method using fluoxetine avoid dependent claim 4 by changing dose?
Dependent claim 4 requires a daily adult fluoxetine dose of about 2 mg to about 80 mg. Materially outside that range can reduce literal infringement risk for that dependent claim.
-
What makes Claims 5-8 distinct from Claims 1-4?
Claims 5-8 require that the psychiatric symptoms are associated with premenstrual disorders, adding a clinical-context limitation beyond symptom identity.
-
How important is “nontoxic dose” to infringement?
It is an express limitation in the claims. The method requires administration of a nontoxic dose, which typically aligns with clinically safe dosing but still functions as a claim boundary.
References
[1] United States Patent 5,789,449.
